Fibrinogen 350mg/5ml solution for sealant vials
Requires a prescription from a doctor or prescriber
Fibrinogen concentrate (human) is a hematological agent.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Fibrinogen human
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Fibrinogen human on the MHRA register
Fibrinogen 350mg/5ml solution for sealant vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 6 · Randomised trials: 4 · 1992–2026
Showing the 50 most relevant studies, sorted by most relevant.
Behera S, Sahoo N, Sahu S
2026
Bao Z, An J, Li G, et al.
2026
- Carcinoma, Renal Cell
- Urologic Neoplasms
- Serum Albumin
BackgroundGrowing evidence indicates that the pre-operative ratio of fibrinogen to albumin (FAR/AFR) can act as a prognostic predictor for different kinds of cancer. Although a previous meta-analysis briefly involved urological malignancies, it only incorporated one study for bladder cancer (BC) and one for renal cell carcinoma (RCC) with limited data. To date, a comprehensive and systematic quantitative assessment of plasma FAR/AFR as a prognostic indicator in urological cancers remains lacking.ObjectiveThis meta-analysis intended to comprehensively investigate the prognostic significance of plasma FAR/AFR in individuals with urological malignancies.MethodsA thorough search of the PubMed, Embase, and Web of Science databases was carried out up to March 2026, leading to the incorporation of 6 studies for this meta-analysis. The research computed hazard ratios (HRs) together with their 95% confidence intervals (CIs) to evaluate disease-free survival (DFS), overall survival (OS), and cancer-specific survival (CSS).ResultsThe study included a total of 1,603 participants. Patients suffering from RCC and BC who showed an increase in pre-operation FAR or a decrease in pre-operation AFR had poorer overall survival (combined HR = 2.36, 95% CI = 1.92-2.91; p ConclusionsIncreased FAR or decreased AFR act as independent markers of unfavorable survival prognosis in patients with RCC and BC.
Abstract licence: CC BY-NC-ND
Ibrahim Z, Murphy RP, Guillaume GC, et al.
2026
- Thrombosis
- Biological Clocks
- Circadian Rhythm
Long-duration space missions expose astronauts to microgravity, radiation, confinement, fluid redistribution, and circadian disruption, which together induce physiological adaptations, including cardiovascular hemodynamics. Emerging evidence suggests that spaceflight may modulate hemostasis and potentially increase thrombotic risk in the head/neck; however, the association of circadian disruption and hemostasis in space, and its ground-based analogs, has yet to be systematically evaluated. This systematic review aimed to synthesize evidence from real-spaceflight missions and ground-based analogs to (i) characterize thrombosis-related and hemostatic adaptations, (ii) evaluate circadian remodeling under altered gravitational conditions, and (iii) identify mechanistic and methodological gaps linking biological timing to coagulation regulation in space. A systematic search of PubMed, Scopus, and Web of Science was conducted from January 2016 to January 2026. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, studies investigating circadian rhythms, clock-gene regulation, autonomic chronobiology, hemostasis, thrombosis, platelet biology, and coagulation pathways, in spaceflight or spaceflight analogs were systematically screened and analyzed. Thirty-eight studies met inclusion criteria, of which 20 (52.6%) primarily examined hemostasis and thrombosis outcomes and 18 (47.4%) focused on circadian regulation. Thrombosis-related investigations demonstrated dynamic modulation of coagulation cascades, platelet activation pathways, fibrinogen levels, endothelial markers, and complement components across dry immersion, head-down bed rest, animal unloading models, radiation exposure, hypergravity, and real astronaut missions. However, most hemostatic studies relied on end point or milestone-based sampling without circadian-phase resolution. In contrast, circadian-focused studies used dense temporal sampling and revealed phase shifts, altered autonomic rhythmicity, and disruption of molecular clock regulators under simulated and real space conditions, yet rarely assessed direct thrombotic end points. Importantly, no included study simultaneously assessed circadian-phase regulation and hemostatic outcomes, highlighting a critical lack of mechanistic evidence linking biological timing to thrombotic regulation in spaceflight environments. The absence of circadian phase-resolved hemostatic assessment represents a fundamental mechanistic gap. Future integrative chronothrombotic study designs are required to determine whether disrupted biological timing directly contributes to thrombotic vulnerability during spaceflight.
Abstract licence: CC BY-NC-ND
Xiu-Min Li, Denise Serebrisky, Soo-Young Lee, et al.
Journal of Allergy and Clinical Immunology, 2000
Eric Jauniaux, Adrian Watson, Graham Burton
American Journal of Obstetrics and Gynecology, 2001
E.A. Smith, G.T. Macfarlane
Microbial Ecology, 1997
Alan Sugar, MD, Munira Hussain, MS, Winston Chamberlain, MD, PhD, et al.
Ophthalmology Science, 2022
Martin A. Schick, Jonas Pippir, Manuel F. Struck, et al.
BMC Research Notes, 2021
Dorothy L. Patton, Soe Soe Thwin, Amalia Meier, et al.
American Journal of Obstetrics and Gynecology, 2000
Everett F. Magann, Maureen Sanderson, James N. Martin, et al.
American Journal of Obstetrics and Gynecology, 2000
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Fibrinogen (factor I) is a soluble plasma glycoprotein with a molecular weight of about 340 kDa.
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
[L41065]
It is also indicated for fibrinogen supplementation in bleeding patients with acquired fibrinogen deficiency.
[L41065]
In combination with thrombin, it is used indicated as an adjunct to hemostasis for mild to moderate bleeding in adults undergoing surgery when control of bleeding by standard surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical.
[L12936][L12939]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 91 interactions
ATC B02BB01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Fibrinogen human
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72